Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives | WAPE

Newsbenzinga

FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives

Oct 7, 2026, 14:28 ET · Published

Article summary

FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives

An excerpt from the original article.

Related companies

NVSNVSView stock

Comments —

Comment

Loading comments…